Clinical Trial Update: Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial of docetaxel plus bevacizumab in elderly patients with stage IV non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: NSCLC | Phase 2 | Status: TERMINATED